OOIR: Observatory of International Research

Papers

(The TQCC of Drug Resistance Updates is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Editorial Board	418
Modulating undruggable targets to overcome cancer therapy resistance	271
Editorial Board	218
Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer	192
PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor	180
Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor	162
N6-methyladenosine modification of 3'tRF-AlaAGC impairs PD-1 blockade efficacy by promoting lactic acid accumulation in the tumor microenvironment of gastric carcinoma	149
Plasmid-borne tigecycline resistance gene tet(X4) in Salmonella enterica and Escherichia coli isolates from a pediatric patient with diarrhea	142
Novel nanomedicines to overcome cancer multidrug resistance	139
Profiling the landscape of carbapenem resistance and hypervirulence in Klebsiella pneumoniae: A global epidemiological analysis of the plasmidome	125
Unraveling the secrets: Evolution of resistance mediated by membrane proteins	124
Sciatic nerve stimulation enhances NK cell cytotoxicity through dopamine signaling and synergizes immunotherapy in triple-negative breast cancer	122
Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma	106
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects	106
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance	105
Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies	104
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine	103
Editorial Board	101
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer	101
Evolution of RND efflux pumps in the development of a successful pathogen	99
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance	93
Point mutation P174L of the penA gene endowing ceftazidime resistance to Burkholderia pseudomallei in China	90
Collateral sensitivity between tetracyclines and aminoglycosides constrains resistance evolution in carbapenem-resistant Klebsiella pneumoniae	85
A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis	81
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges	79

Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma	78
Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs	73
The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond	72
TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770–5p axis in PDAC	69
Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer	68
Enzymatic bionanocatalysts for combating peri-implant biofilm infections by specific heat-amplified chemodynamic therapy and innate immunomodulation	65
Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs	65
Targeting anoikis resistance as a strategy for cancer therapy	61
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer	57
Editorial Board	57
Novel mobile colistin resistance gene mcr-4.9 in Vibrio cholerae from migratory birds	56
Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma	54
Global population structure and genomic surveillance framework of carbapenem-resistant Salmonella enterica	54
Heterogeneity of SOS response expression in clinical isolates of Escherichia coli influences adaptation to antimicrobial stress	53
Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers	52
Emergence of silent NDM-1 carbapenemase gene in carbapenem-susceptible Klebsiella pneumoniae: Clinical implications and epidemiological insights	48
Research progress on gene mutations and drug resistance in leukemia	48
Current therapy and drug resistance in metastatic castration-resistant prostate cancer	47
Editorial Board	46
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity	46
Overcoming cancer chemotherapy resistance by the induction of ferroptosis	46
Editorial Board	45
Emergence of novel Klebsiella pneumoniae ST types with multidrug resistance in clinic	44
Organoid models of drug resistant gastric adenosquamous carcinoma: Recapitulating tumor features and refining precision treatment	43
ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C	43
Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy	43
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment	40
Global distribution and genomic characteristics of carbapenemase-producing Escherichia coli among humans, 2005–2023	40
Autophagy in cancer development, immune evasion, and drug resistance	39
Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance	38
MicroRNA-mediated PTEN downregulation as a novel non-genetic mechanism of acquired resistance to PI3Kα inhibitors of head & neck squamous cell carcinoma	38
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade	38
Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer	38
CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance	37
Targeting SLC7A11 with sorafenib sensitizes stereotactic body radiotherapy in colorectal cancer liver metastasis	37
Hypoxia as a driver of resistance to immunotherapy	36
Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma	36
CEA-induced PI3K/AKT pathway activation through the binding of CEA to KRT1 contributes to oxaliplatin resistance in gastric cancer	36
LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein	35
Harnessing mitochondrial metabolism and drug resistance in non-small cell lung cancer and beyond by blocking heat-shock proteins	34
Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance	32
Acetate utilization promotes hormone therapy resistance in prostate cancer through neuroendocrine differentiation	32
Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer	32
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer	31
Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer	31
Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance	30
Folylpolyglutamate synthetase inactivation in relapsed ALL induces a druggable folate metabolic vulnerability	30
Characterization difference of typical KL1, KL2 and ST11-KL64 hypervirulent and carbapenem-resistant Klebsiella pneumoniae	30
Solving the antibacterial resistance in Europe: The multipronged approach of the COST Action CA21145 EURESTOP	30
Characterization of NMCR-3, NMCR-4 and NMCR-5, three novel non-mobile colistin resistance determinants: Implications for MCR-3, MCR-7, and MCR-5 progenitors, respectively	29

Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA	28
Emerging Role of Sialylation in Cancer Therapy Resistance: Mechanisms and Therapeutic Implications	28
NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1	28
Breaking the barrier: Epigenetic strategies to combat platinum resistance in colorectal cancer	28